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Data obtained from multiple sources indicate that no single mechanism can explain the resistance to chemotherapy exhibited
by non-small cell lung carcinomas. The multi-factorial nature of drug resistance implies that the analysis of comprising
expression proﬁles may predict drug resistance with higher accuracy than single gene or protein expression studies. Forty
cellular parameters (drug resistance proteins, proliferative, apoptotic, and angiogenic factors, products of proto-oncogenes, and
suppressor genes) were evaluated mainly by immunohistochemistry in specimens of primary non-small cell lung carcinoma of
94 patients and compared with the response of the tumours to doxorubicin in vitro. The protein expression proﬁle of non-
small cell lung carcinoma was determined by hierarchical cluster analysis and clustered image mapping. The cluster analysis
revealed three different resistance proﬁles. The frequency of each proﬁle was different (77, 14 and 9%, respectively). In the
most frequent drug resistance proﬁle, the resistance proteins P-glycoprotein/MDR1 (MDR1, ABCB1), thymidylate-synthetase,
glutathione-S-transferase-p, metallothionein, O
6-methylguanine-DNA-methyltransferase and major vault protein/lung
resistance-related protein were up-regulated. Microvessel density, the angiogenic factor vascular endothelial growth factor
and its receptor FLT1, and ECGF1 as well were down-regulated. In addition, the proliferative factors proliferating cell nuclear
antigen and cyclin A were reduced compared to the sensitive non-small cell lung carcinoma. In this resistance proﬁle, FOS was
up-regulated and NM23 down-regulated. In the second proﬁle, only three resistance proteins were increased (glutathione-S-
transferase-p,O
6-methylguanine-DNA-methyltransferase, major vault protein/lung resistance-related protein). The angiogenic
factors were reduced. In the third proﬁle, only ﬁve of the resistance factors were increased (MDR1, thymidylate-synthetase,
glutathione-S-transferase-p,O
6-methylguanine-DNA-methyltransferase, major vault protein/lung resistance-related protein).
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Lung cancer remains a major cause of morbidity and mortality in
Western countries. The majority of bronchogenic carcinomas can
be classiﬁed into four histological types: small cell lung carcinomas,
squamous cell lung carcinomas, adenocarcinomas, and large cell
lung carcinomas. Histological features, ultra-structure, clinical
course, and response to therapy indicate that small cell lung cancer
is a separate entity. The other three histological subtypes are
referred to as non-small cell lung cancer (NSCLC). While small cell
lung carcinomas are among the most drug sensitive tumours,
NSCLC are frequently resistant to drug therapy and obtaining a
complete response is rare. Therefore, the drug resistance in patients
receiving chemotherapy alone or when combined with radiother-
apy represents a major problem in cancer treatment of patients
with NSCLC.
Data obtained from multiple sources indicate that no single
mechanism can explain the resistance to therapy exhibited by
NSCLC. The resistance mechanisms are numerous and diverse
(Valeriote and van Putten, 1975; Bradley et al, 1988; Kelley et al,
1988; Scanlon and Kashani-Sabet, 1988; Whelan et al, 1989; Huot
et al, 1991; Kaina et al, 1991, Volm et al, 1991; Kooma ¨gi et al,
1995; Hickman, 1996; Volm and Mattern, 1996; Volm and Rittgen,
2000). They depend on the detoxifying capacity of the cells, repair
capacity, drug delivery, cell proliferation and many other factors.
Therefore, a key challenge is to determine the relative quantitative
contributions of each of these mechanisms to the drug resistant
phenotype. In order to understand the complex network of genes
in clinically relevant drug resistance, it is rather not sufﬁcient to
investigate single genes. Holistic analyses of an entire battery of
genes conferring drug resistance may be more appropriate to gain
insight into the full potential of unresponsive tumours.
In an endeavour to cope with the complex resistance mechan-
isms, in this investigation 40 cellular parameters were evaluated
in specimens of NSCLC of 94 patients. The purpose of this study
was to determine the resistance proﬁles of NSCLC by hierarchical
cluster analysis.
MATERIALS AND METHODS
Patients and tumours
Ninety-four patients (83 men, 11 women) with previously
untreated NSCLC were admitted to this study. All patients were
surgically treated at the Chest Hospital in Heidelberg-Rohrbach.
The morphological classiﬁcation of the carcinomas was conducted
according to the WHO speciﬁcations. Of the carcinomas, 48 were
squamous carcinomas, 34 were adenocarcinomas and 12 were large
cell carcinomas. All patients were staged at the time of their surgery
according to the guidelines of the American Joint Committee on
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www.bjcancer.comCancer. Sixteen patients had stage I, 12 patients stage II and 66
patients had stage III tumours. The mean age of the patients was
59 years.
Detection of tumour resistance in vitro
Most of the patients were treated by surgical procedures alone.
Only a small group of patients were treated by combined surgical
and radiation treatment or chemotherapy but the additional radia-
tion treatment and chemotherapy had no signiﬁcant effect on
patient survival time (P40.1) and on the cluster analysis. For
determining the resistance of tumours we used a short-term in
vitro test that has been described previously (Volm et al, 1979,
1988a). Its basic feature is measurement of changes in the incor-
poration of radioactive nucleic acid precursors into tumour cells
after addition of doxorubicin. We found that anthracyclines (e.g.
doxorubicin) can be used as reference compound for multiple
resistance. Tumours were deﬁned as being sensitive or resistant
depending on whether nucleotide uptake was inhibited by more
or less than 65% at a concentration of doxorubicin of 10 mgm l
71.
This threshold was based on prior clinical correlation (Volm et al,
1979).
Immunohistochemistry
The previously described method was used to detect the proteins in
formalin-ﬁxed and parafﬁn-embedded specimens (Volm et al,
1991, 1998; Kooma ¨gi and Volm, 1999). Brieﬂy, formalin-ﬁxed
and parafﬁn-embedded tissue were deparafﬁnised. After pre-incu-
bation with hydrogen peroxide and protein blocking solution, the
primary antibodies were applied for 16 h at 48C. After incubation
with secondary antibodies, the streptavidin biotinylated peroxidase
complex was added and the peroxidase activity visualised with 3-
amino-9-ethylcarbazole. Counter-staining was performed with
haematoxylin. Both negative and positive controls were conducted.
Negative controls were prepared by omitting the primary antibo-
dies and by substituting irrelevant antibodies for the primary
antibodies. The speciﬁcity of the reactions were proved by Western
blots. Three observers independently evaluated the results from the
immunohistochemical staining without having any prior know-
ledge of an individual patient’s clinical data. The evaluations
agreed in 90–95% of the samples. The other specimens (5–
10%) were re-evaluated and then classiﬁed according to the classi-
ﬁcation most frequently given by the observers. To evaluate the
protein expression, the staining intensity or the staining intensity
and the percentages of positive cells were determined.
A part of the antibodies for the detection of resistance-proteins
were gifts from several laboratories, others were commercially
available. The appropriate concentrations were found by additional
experiments. Anti-glutathione S-transferase-p (GSTP1) was kindly
donated by Dr K Satoh (University School of Medicine, Hirosaki,
Japan) anti-DNA topoisomerase II (TOP2A) by Dr L Liu (John
Hopkins Oncology Center, Baltimore, MD, USA); anti-metallothio-
nein (MT) by Dr PC Huang (Johns Hopkins University, Baltimore,
MD, USA); anti-thymidylate synthetase (TYMS) by Dr B Yates
(Burroughs Welcome, Research Triangle Park, Cornwallis USA);
and anti-O
6-methylguanine-DNA-methyl-transferase (MGMT) by
Dr B Li (University Singapore, Singapore). The anti-P-glycoprotein
(MDR1, ABCB1) antibody JSB-1 was obtained from Sanbio (Uden,
Netherlands); anti-catalase (CAT) from Calbiochem (La Jolla, CA,
USA); anti-heat shock protein 70 (HSPA1A) from Dako Diagnos-
tika (Hamburg, Germany), and anti-major vault protein/lung
resistance-related protein (MVP/LRP) from Dunn Labortechnik
(Asbach, Germany). For detection of the proliferative activity,
anti-cyclin A (CCNA), anti-CDK2 and anti-CDK4 were obtained
from Santa Cruz Biotechnology (Heidelberg, Germany). Anti-cyclin
D1 (CCND) was from Calbiochem/Novabiochem (Baden-Soden,
Germany) and PCNA from Dianova (Hamburg, Germany). The
antibody for detection of the apoptotic factor FAS/CD95
(TNFRSF6) was from Immunotech (Hamburg, Germany) and
anti-FAS ligand (TNFSF6) and anti-caspase 3 (CASP3) from Santa
Cruz Biotechnology. The antibodies for staining of angiogenic
factors were anti-VEGF obtained from Dianova, anti-tissue factor
(TF, F3) from Biodesign (Kennebunk, MA, USA), anti-bFGF,
anti-FGFR and anti-FLT1 from Santa Cruz Biotechnology. Anti-
angiostatin was purchased from Oncogene Research Products
(Cambridge, MA, USA). Anti-PD-ECGF (ECGF1) was a gift from
Dr Tanaka (Nippon Roche Research Centre, Kamakura, Japan).
For the detection of the proto-oncogene and suppressor gene
products we used the following antibodies: c-K-ras (KRAS), c-H-
ras (HRAS), c-N-ras (NRAS), FOS, JUN, MYC, ERBB1, ERBB2,
RB1 and p53 (TP53). All antibodies for the above mentioned
proto-oncogene and suppressor gene proteins were from Dianova.
Anti-BCL2 was from Oncogene Research Products and anti-
p16
INK4A (CDKN2A) was from Santa Cruz Biotechnology.
Anti-NM23 was obtained from Novocastra (Newcastle-upon-
Tyne, UK) and anti-HIF-1a (HIF1A) and anti-HIF-1b (HIF1B)
from Novus Biologicals (Littleton, CO, USA).
Measurement of micro-vessel density
Blood vessels were highlighted by staining endothelial cells for
factor VIII using the strepatavidin-biotin peroxidase complex
method. Micro-vessel density was determined by counting labelled
capillaries in the areas of highest vascularisation within the tumour
mass. Individual counts of blood vessels were determined by light
microscopy in a 2506 ﬁeld as described earlier (Weidner et al,
1991).
Assessment of apoptosis
Apoptotic cell death was detected with a non-radioactive 3'-end
DNA labelling technique which used the in situ cell death detection
kit (TUNEL reaction). The procedure was described earlier
(Stammler and Volm, 1996).
DNA cell cycle analysis by ﬂow cytometry
A mixture of propidium iodide and 4'-6-diamidino-2-phenylindole
was applied simultaneously with RNAse after methanol ﬁxation
and protease digestion of single cell suspensions (Volm et al,
1988b). Flow cytometry analysis was undertaken with an ICP-22
(Phywe, Go ¨ttingen, Germany). Peripheral blood leukocytes from
healthy donors were used as a calibration standard for DNA diploi-
dy. Parallel measurements, both including and omitting the
standard, were performed. The cell cycle analysis was performed
using integrated Gaussian ﬁttings. A computerised subtraction of
exponentially decreasing corrections beginning with the peak of
cellular debris was included in the evaluation program. The cell
cycle analysis was omitted in cases that exhibited interspersed cell
populations.
Statistical analysis
The doxorubicin resistance parameter (short-term test) is expressed
as a percentage of the controls. These values deﬁne a ‘sensitive’
group (less than 65% at a concentration of 10
72 mg ml
71 doxor-
ubicin) and a ‘resistant’ group (not less than 65%). This
classiﬁcation is used later on to examine whether other parameters
show signiﬁcant relationships.
The immunohistochemical parameters were evaluated on either
a binary scale (‘no reaction’ or ‘reaction’, coded as ‘7’ or ‘+’)
or an ordinal scale ‘no reaction’, ‘weak’, ‘moderate’ or ‘strong reac-
tion’ (coded as ‘7’, ‘+’, ‘++’ or ‘+++’). The apoptotic indices,
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ables and, therefore, the median values were used. To ﬁnd out
the predictive value of these parameters with respect to doxorubi-
cin resistance Fisher’s exact tests were performed. The results of
these tests with P-values 50.1 are summarised in Table 1. The
parameters with a P value greater than 0.1 were not analysed any
further.
Hierarchical cluster analysis is an explorative statistical method
and aims to group at ﬁrst sight heterogeneous objects into clusters
of homogeneous objects. Objects are classiﬁed by calculation of
distances according to the closeness of between-individual
distances. All objects are assembled into a cluster tree (dendro-
gram). Thus, objects with tightly related features appear together,
while the separation in the cluster tree increases with progressive
dissimilarity. Cluster analyses applying average- or complete-link-
age methods were done by means of the WinSTAT program
(Kalmia Company). Missing values are automatically omitted by
the program and the closeness of two joined objects was calculated
by the number of data points they contained. In order to calculate
distances of all variables included in the analysis, the program
automatically standardises the variables by transforming the data
with a mean=0 and a variance=1. To construct clustered-image
maps (CIM), two dendrograms were related to each other. The
16 resistance factors were cluster-ordered on the basis of their
expression pattern across the 94 NSCLC. Thus, resistance para-
meters with most nearly identical pattern appear side by side on
the x-ordinate. Vice versa, the 94 NSCLC were cluster-ordered
across the resistance factors. Tumours with most identical expres-
sion patterns of resistance factors appear side by side on the y-
co-ordinate.
RESULTS
The objective of this investigation was to evaluate the proﬁle of
protein expression involved in resistant NSCLC. For this reason,
the expressions of 40 factors in primary NSCLC of 94 patients were
determined and correlated with the data obtained by the in vitro
resistance test. Examples are given in Figure 1. Of the 94 patients
with NSCLC 70 patients had resistant carcinomas, whereas 24
patients revealed sensitive carcinomas. As visible in Figure 1, P-
glycoprotein is positively correlated with resistance while VEGF is
negatively correlated.
In a ﬁrst step, we analysed the relationships of the expression
levels of the 40 factors with sensitivity/resistance by Fisher’s exact
tests. Of the investigated resistance proteins P-glycoprotein/
MDR1 (MDR1, ABCB1), glutathione-S-transferase-p (GSTP1),
metallothionein (MT), O
6-methyl-guanine-DNA-methyltransferase
(MGMT), lung resistance-related protein (MVP/LRP), thymidy-
late synthetase (TYMS), DNA-topoisomerase II (TOP II),
catalase (CAT) and heat shock protein 70 (HSP 70) six proteins
(MDR1, TYMS, GSTP1, MT, MGMT and MVP/LRP) showed a
relationship to sensitivity/resistance (P50.1) (Table 1). These
six proteins were increased in resistant NSCLC. Of the prolifera-
tive factors analysed (PCNA, cyclin A, cyclin D, the cyclin-
dependent kinases cdk2 and cdk4, cell cycle phases) only PCNA
and cyclin A (CCNA) exhibited a relationship to sensitivity/resis-
tance and were down-regulated in resistant carcinomas. Of the
angiogenic proteins tested, vascular endothelial growth factor
(VEGF), its receptor FLT1 and platelet-derived endothelial
growth factor (ECGF1) showed a relationship to sensitivity/resis-
tance. These factors were reduced in resistant carcinomas. This
was conﬁrmed by the reduction of micro-vessel density in resis-
tant tumours (Table 1). Such relationship was not found with
basic ﬁbroblast growth factor (bFGF), its receptor FGFR and
with angiostatin. No relationship exists between the expression
of tissue factor and the resistance of tumours. Of the pro-apop-
totic factors investigated FAS/CD95, FAS ligand, and caspase-3
only FAS/CD95 was signiﬁcantly reduced in resistant NSCLC.
The anti-apoptotic factor BCL-2 showed no obvious relationship
to sensitivity/resistance of NSCLC. There is huge evidence that
proto-oncogenes and suppressor genes are implicated in resis-
tance of tumours. Therefore, we investigated the products of c-
fos,c - jun,c - myc,c - erbB1, c-erbB2, c-K-ras, c-H-ras, c-N-ras,
rb, p53, nm23 and p16
INK4a. Of these proteins only FOS, ERBB2
and NM23 revealed a correlation to sensitivity/resistance of
NSCLC. Finally, hypoxia causes a wide range of responses in
tumours. Therefore, we assessed whether hypoxia-inducible
factors (HIF) may also play a role in the resistance of NSCLC.
Both HIF-1a and HIF-1b did not reveal a relationship to sensi-
tivity/resistance of NSCLC. In Table 1, the 16 factors are listed
which showed relationships to the doxorubicin response of
NSCLC (P50.1) The parameters with P-values greater than 0.1
were not analysed any further.
This kind of analysis, however, does not allow an insight to
complex expression proﬁles which constitute resistant or sensitive
tumour phenotypes. Therefore, we decided to perform hierarchical
cluster analyses which may be more suited to unravel the full
potential of such data sets for an integrated understanding of drug
resistance. We subjected these 16 proteins to hierarchical cluster
analysis, in order to ﬁnd out expression proﬁles indicative for drug
resistance of NSCLC (Figure 2, dendrogram on the right).
We divided the dendrogram into ﬁve clusters and correlated
them with the in vitro resistance data which were not included
as parameter into the cluster analysis (Table 2). Sensitive and resis-
tant NSCLC were separated in the clusters (P=7.58 E
77). Cluster 1
(n=23 cases) is enriched with sensitive carcinomas (78%), while
cluster 2 (n=6 cases), cluster 4 (n=53 cases) and cluster 5 (n=10
cases) were enriched with resistant carcinomas (83, 89 and 90%
respectively). These clusters showed no relationships to other clin-
ical parameters (stage, survival).
The mean values of the 16 parameters of all investigated carci-
nomas of the clusters were measured and the ratios of resistant/
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Table 1 Correlation between doxorubicin resistance as measured by
the in vitro short-term test and various drug resistance factors
P-value
Factor Number of (Fisher’s
groups Factor patients Partition exact test)
Resistance MDR1 (ABCB1) 94 7, + vs ++, +++ 50.01
proteins TYMS 94 7 vs + 50.01
GSTP1 94 7, + vs ++, +++ 50.01
MT 93 7 vs + 0.01
MGMT 91 7, +, ++ vs +++ 0.03
MVP/LRP 87 7, + vs ++, +++ 0.04
Additional ECGF1 75 7 vs +, ++, +++ 0.01
resistance NM23 69 7 vs +, ++, +++ 0.01
factors Micro-vessel density 84 57v s47 0.01
VEGF 82 7 vs +, ++, +++ 0.02
FAS (CD95, TNFRSF6) 60 7 vs + 0.04
CCNA 79 7 vs +, ++, +++ 0.05
ERBB2 91 7 vs +, ++, +++ 0.06
FLT1 85 7 vs ++, +++ 0.07
PCNA 87 7, + vs ++, +++ 0.07
FOS 91 7, + vs ++, +++ 0.09
CCNA=cyclin A; ECGF1=platelet-derived endothelial growth factor; ERBB2=v-erb-
B2 avian erythroblastic leukaemia viral oncogene homologue 2; FAS (CD 95,
TNFRSF6)=tumour necrosis factor receptor super-family, member 6; FLT1=fms-
related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability
factor receptor); FOS=v-fos FBJ murine osteosarcoma viral oncogene homologue;
GSTP1=glutathione S-transferase-p; MDR1 (ABCB1)=multidrug resistance gene 1,
P-glycoprotein, ATP-binding cassette, subfamily B (MDR/TAP), member 1;
MGMT=O
6-methylguanine-DNA-methyltransferase; MT=metallothionein; MVP/
LRP=major vault protein/lung resistance-related protein; NM23=protein expressed
in non-metastatic cells 1; PCNA=proliferating cell nuclear antigen;
TYMS=thymidylate synthetase; VEGF=vascular endothelial growth factor.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(3), 251–257sensitive clusters determined (Table 3). The cluster analysis
revealed that three different resistance proﬁles exist. The frequency
of the resistance proﬁles are different (cluster 4: 77%, cluster 5:
14%, cluster 2: 9%).
Inthemostfrequentdrugresistanceproﬁle(cluster4)allresistance
proteins investigated (MDR1, TYMS, GSTP1, MT, MGMT, MVP/
LRP) were up-regulated. Micro-vessel density and the angiogenic
factors ECGF1, VEGF, FLT1 were down-regulated. Additionally, the
proliferative factors PCNA and CCNA were reduced. The apoptotic
factor FAS/CD95 was less expressed than in sensitive carcinomas.
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Figure 1 Relationship between the drug response (doxorubicin) as determined by the in vitro short term test (ordinate) and the immunohistochemical
reaction of P-glycoprotein/MDR1 and VEGF. The intensity of immunostaining (negative, weak, moderate, high) is speciﬁed as 7, +, ++, +++
Resistant tumours, Type 1
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2. VEGF
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Figure 2 Dendrograms and clustered image map obtained by hierarchical cluster analysis (complete linkage method). The dendrogram on the right shows
the clustering of 94 NSCLC and the dendrogram on the top of 16 resistance factors. Light ﬁelds indicate ‘not expressed’ and dark ﬁelds indicate ‘expressed’
according to the partition for each resistance factor shown in Table 2. Missing values are depicted in white
Table 2 Separation of ﬁve NSCLC clusters obtained by the hierarchical
cluster analysis shown in Figure 2 (right side) and comparison to chemosen-
sitivity. The distribution of sensitive and resistant NSCLC was determined
with the in vitro short-term test. Cut-off of the short-term test: 65%
Cluster 1 2 3 4 5
Sensitive 16 1 1 5 1
Resistant 7 5 1 48 9
P=7.58 E
77 (Fisher exact test).
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while NM23 and ERBB2 were down-regulated.
The analysis of the carcinomas of cluster 5 shows that only
three of the six investigated resistance proteins were up-regu-
lated (GSTP1, MGMT, MVP/LRP). Again, micro-vessel density
was reduced and the angiogenic factors (VEGF, ECGF1) were
more down-regulated than those of the carcinomas in cluster
4. The proliferative and apoptotic factors were reduced. In
contrast to the carcinomas in cluster 4, NM23 was not chan-
ged.
The evidence of the third resistance proﬁle (cluster 2) is
limited because of the small number of carcinomas in this clus-
ter. Only ﬁve resistance proteins (MDR1, TYMS, GSTP1,
MGMT, MVP/LRP) were increased in comparison to sensitive
tumours, while the other resistance factors revealed only marginal
changes.
Next, we performed a cluster analysis using the 16 resistance
factors and found a dendrogram which can be separated into three
areas (Figure 2, top). The ﬁrst area obtained three parameters
(VEGF, MGMT and GSTP1). The second area contained in their
majority proliferation- or angiogenesis-regulating proteins (e.g.
ERBB2, PCNA, ECGF1, FLT1, and CCNA). In the third area were
genes known to contribute to drug resistance and apoptosis (FAS/
CD95, MT, TYMS, FOS, MDR1).
As shown in Figure 2, the CIM can be subdivided into several
areas (A to O). The sensitive NSCLC (CIM areas M and O) were
characterised by a less frequent expression of drug resistance
proteins than resistant tumours of CIM areas D and F. On the
other hand, these resistant tumours revealed a lower expression
of proliferation/angiogenesis-regulating proteins (CIM area E)
compared to sensitive tumours (CIM area N). The tumours
grouped in CIM areas A to C were resistant as well, but they
showed a different protein expression proﬁle compared to the
resistant tumours of CIM areas D to F. These NSCLC exhibited
a rather low expression of drug resistance genes (except MGMT
and GSTP1; CIM area A) and proliferation/angiogenesis-regulating
proteins (CIM areas B and C). Resistant tumours of CIM areas J to
L consisted of only few cases, but they seem to be distinct from the
other resistant tumours of CIM areas A to I with a strong expres-
sion of all proteins investigated. Cluster 3 consisted of only two
tumours and are thus less informative (CIM areas G to I). The
clustering was independent of stage of tumours (P40.9) and of
survival of patients (P40.7).
DISCUSSION
The advances in molecular and cellular biology have opened new
avenues for the characterisation of drug resistant tumours. Protein
and RNA expression are in the centre of interest. Protein detection
by immunohistochemistry and RNA detection by Northern blot-
ting or reverse transcription-polymerase chain reaction (RT–
PCR) may be more suited for clinical application than assays such
as Western blotting or RNAse protection assay. In this study, we
used mainly immunohistochemical assays to analyse expression
proﬁles of proteins of NSCLC.
To analyse the effect of doxorubicin, we used the nucleotide
incorporation test (in vitro short-term test), because the patients
were operated only. Previously, different in vitro test systems (tissue
culture assay, colony assay and short term test) to monitor the
resistance were compared and similar results with all three methods
were obtained (Volm et al, 1987). In a clinical study, 55 of 57
tumours that were resistant in the short-term test were also clini-
cally progressive (Group for Sensitivity Testing of Tumors (KSST),
1981). Several authors have conﬁrmed this consistency between in
vitro test results and the clinical results (Auner et al, 1989; Khoo et
al, 1989). These evidences let us believe that the in vitro short term
is suitable to determine the resistance of NSCLC.
There is striking evidence that a wide variety of drug resistance
mechanisms are operational in clinically relevant drug resistance. In
this analysis, several resistance proteins and additional resistance-
related factors were changed in resistant NSCLC in comparison
to sensitive carcinomas. The reason for this concomitant expression
of different factors may be the result of inducing a cascade of resis-
tance-related gene products that can be triggered by environmental
factors such as smoking (Volm et al, 1991, 1999; Mattern et al,
1998). Another possible explanation is that lung cancer is mostly
detected at a relatively late stage. These carcinomas are mainly
hypoxic and the vascular network that supplies oxygen and nutri-
ents is substantially lower. In fact, in our study the micro-vessel
density and several angiogenic factors were reduced in resistant
NSCLC.
Data obtained in a variety of systems show that the proliferation
may also be an important resistance factor (Kohn et al, 1994;
Cordon-Cardo, 1995). Indeed, we found in the present study that
the proliferative factors were decreased in resistant NSCLC. Apop-
tosis or programmed cell death is an important homeostatic
mechanism that balances cell production with cell death (Thomp-
son, 1995). In our analysis, FAS/CD95 was also lower in resistant
NSCLC compared to sensitive carcinomas.
Because indications exist that proto-oncogenes and tumour
suppressor genes may be implicated in tumour resistance (Burt
et al, 1988), we examined the expressions of the proteins of some
of these factors. In our analysis, the expressions of ERBB2, NM23,
and FOS played an important role in resistant NSCLC. ErbB2
encodes a protein that acts as a transmembrane growth factor
receptor and showed a similar reaction as the proliferative factors
CCNA and PCNA on the response. NM23 which is a putative
metastasis suppressor gene has also been shown to be associated
with cell proliferation and apoptosis (Venturelli et al, 1995). FOS
and JUN constitute the AP-1 protein complex which binds speciﬁ-
cally to the AP-1 binding site in promotors of resistance genes
(Teeter et al, 1991). Though this is known for a decade, the full
relevance of AP1 and FOS may have been underestimated as of yet.
The multi-facetted nature of drug resistance implies that the
analysis of entire expression proﬁles may predict drug resistance
with higher accuracy and may be superior to single gene expression
studies. By means of clustered image mapping (CIM) we found
four different protein expression proﬁles. One expression proﬁle
was characterised by low expression of drug resistance proteins
and high expression of proliferation/angiogenesis-regulating
proteins (CIM areas M to O). This expression proﬁle was indica-
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Table 3 Ratio (resistant/sensitive) of the parameters in different clusters
obtained in the dendrogram shown in Figure 1 (right side)
Ratio Ratio Ratio
Cluster 4/1 Cluster 5/1 Cluster 2/1
MDR1 (ABCB1) 2.0 1.0 2.2
TYMS 2.3 0.8 2.6
GSTP1 2.0 1.8 2.7
MT 1.8 0.8 1.1
MGMT 2.5 3.4 3.6
MVP/LRP 12.5 8.0 26.0
ECGF1 0.4 0.1 0.8
NM3 0.1 1.1 1.5
Micro-vessel density 0.6 0.6 1.0
VEGF 0.7 0.1 0.9
FAS (CD95, TNFRSF6) 0.6 0.7 1.4
CCNA 0.6 0.7 1.0
ERBB2 0.5 0.4 1.6
FLT1 0.6 0.6 1.0
PCNA 0.4 0.1 1.4
FOS 1.7 1.5 0.9
Abbreviations: see legend to Table 1.
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tumours were visible by means of CIM. Type 1 revealed a high
expression of drug resistance genes and a lower expression of
proliferation/angiogenesis-regulating proteins (CIM areas D to F).
The majority of tumours belonged to this group indicting that this
expression proﬁle is the most important for NSCLC. Type 2 is
characterised by a low or intermediate expression of drug resistance
genes and a rather low expression of proliferation/angiogenesis-
regulating proteins. Thus, this type of resistance seemed predomi-
nately to be due to a decreased proliferative and angiogenetic
capacity of tumours. Type 3 consisted of few resistant tumours
with high expression of drug resistance as well as proliferation/
angiogenesis-associated proteins. As a high expression of prolifera-
tive and angiogenetic markers contribute rather to
chemosensitivity, the high expression of drug resistance proteins
may be superior for the expression of a resistant phenotype. This
analysis gives a clue that the molecular architecture of drug resis-
tance is far more complex as estimated as of yet and that
different types of expression proﬁles are responsible for the devel-
opment of drug resistance. The high prediction of in vitro
resistance (83–90%) which resulted from the combined cluster
calculation of 16 proteins is clearly superior to the prediction of
resistance by any single of these proteins. It can, thus, be inferred
from the CIM data that chemotherapy would be more beneﬁcial to
patients with sensitive tumours of CIM areas M to O than to
patients with resistant tumours of CIM areas A to F and J to L).
These results may have important implications for diagnosis and
therapy of NSCLC. Our data envision the deﬁnition of character-
istic resistance gene proﬁle able to predict clinical response to
chemotherapy. Although the statistical probability of the resistance
proﬁle of NSCLC may be known, the clinical response of the indi-
vidual patient remains still uncertain. However, the recently
thriving micro-array technology may allow simultaneous analyses
of thousands of genes of a single patient in a single experiment
(Shim et al, 1998; Golup et al, 1999; Sgroi et al, 1999; Ono et al,
2000; Ross et al, 2000; Scherf et al, 2000). The idea to generate a
predictive test for lung cancer patients is gaining ground with such
novel approaches. This concept embodies to develop individual
cytostatic treatment schedules for each patient. On the other hand,
it has been suggested that a minimal set of about 10 to 50 genes
may provide more robust results than sets of thousands of genes
(Wooster, 2000). It is still open to discussion, whether results
obtained from large-scale gene expression experiments may be of
limited utility for routine diagnostics and whether the wealth of
genes not involved in resistance produce a high background which
masks the view of the relevant genes. The resistance proteins and
the resistance-related factors which we found in the present analy-
sis may be suitable parameters to predict treatment response of
NSCLC. We believe that these parameters together with hierarchi-
cal cluster analysis as appropriate tool to identify responding or
non-responding tumours are determinants which will ease the
development of a predictive test methodology for NSCLC.
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